Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Birgit Geoerger, Bruce Morland, Irene Jim énez, Didier Frappaz, Andrew D.J. Pearson, Gilles Vassal, Patricia Maeda, Jasmine Kincaide, Udo Mueller, Sarah Schlief, Michael Teufel, Bart A. Ploeger, Adriaan Cleton, Andrea C. Agostinho, Lynley V. Marshall Tags: Original Research Source Type: research